Group 1 - The company expects a significant decline in net profit, projecting a decrease of over 50% for the fiscal year 2025 [1] - The performance forecast period is from January 1, 2025, to December 31, 2025, with net profit anticipated to be positive but substantially lower than the previous year [1] - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies noted, pending the final audit results [1] Group 2 - The decline in revenue is attributed to increased market competition and changes in market demand, which have also led to a decrease in product prices [1] - Financial expenses have increased significantly year-on-year, primarily due to foreign exchange losses resulting from currency fluctuations, further impacting profit levels [1]

Core Viewpoint - Wuzhou Medical (301234) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 47.46% to 59.97% compared to the previous year [1][3] Trading Information Summary - On January 29, 2026, Wuzhou Medical closed at 40.38 yuan, down 0.54%, with a turnover rate of 1.05%, a trading volume of 7,143 lots, and a transaction amount of 28.97 million yuan [1] - On the same day, the net inflow of funds from major investors was 1.23 million yuan, while retail investors experienced a net outflow of 4.01 million yuan [1][3] Performance Disclosure Highlights - Wuzhou Medical has released a performance forecast for 2025, estimating a net profit attributable to shareholders of 16 million to 21 million yuan, which represents a year-on-year decline of 47.46% to 59.97% [1][3] - The company also anticipates a net profit of 11 million to 16 million yuan after deducting non-recurring gains and losses, reflecting a decrease of 54.98% to 69.05% year-on-year [1] - The decline in performance is attributed to reduced operating income, falling product prices, and increased exchange losses due to currency fluctuations [1]

Core Viewpoint - Wuzhou Medical (301234) is expected to report a significant decline in net profit for the fiscal year 2025, with projections indicating a drop of 47.46% to 59.97% compared to the previous year [1] Group 1: Stock Performance - As of January 29, 2026, Wuzhou Medical's stock closed at 40.38 yuan, down 0.54% from the previous trading day [1] - The stock opened at 40.9 yuan, reached a high of 41.2 yuan, and a low of 40.2 yuan, with a trading volume of 28.97 million yuan and a turnover rate of 1.05% [1] Group 2: Financial Forecast - The company forecasts a net profit attributable to shareholders of between 16 million yuan and 21 million yuan for 2025 [1] - The net profit after deducting non-recurring gains and losses is expected to be between 11 million yuan and 16 million yuan, representing a year-on-year decline of 54.98% to 69.05% [1] - The decline in performance is attributed to reduced operating income, falling product prices, and increased exchange losses due to currency fluctuations [1]

证券代码：301234 证券简称：五洲医疗 公告编号：2026-001 安徽宏宇五洲医疗器械股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 单位：万元 本次业绩预告的相关财务数据未经会计师事务所审计。公司已就本次业绩 预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在业绩预告 方面不存在分歧，具体情况以审计结果为准。 三、业绩变动原因说明 1、报告期内，受行业市场竞争及市场需求变化等因素的影响，公司营业 收入有一定程度减少，同时市场竞争导致产品价格有所下降，导致公司净利润 出现较大幅度下滑。 2、报告期内，公司财务费用同比有较大幅度增加，主要系汇率波动导致 公司汇兑净损失增加，进一步降低了公司的利润水平。 四、其他相关说明 本次业绩预告数据是公司财务部门初步核算的结果，未经会计师事务所审 计。公司 2025 年度 ...

证券日报网讯 1月28日，五洲医疗在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东 总户数为5364户。 （文章来源：证券日报） ...

Core Viewpoint - Wuzhou Medical (301234) reported a slight increase in stock price but faced significant declines in net profit and revenue in the latest financial results [1][2]. Financial Performance - For the first three quarters of 2025, Wuzhou Medical achieved a main operating revenue of 345 million yuan, a year-on-year increase of 0.82% [2]. - The net profit attributable to shareholders was 18.51 million yuan, reflecting a year-on-year decrease of 46.09% [2]. - The net profit after deducting non-recurring gains and losses was 14.82 million yuan, down 45.3% year-on-year [2]. - In Q3 2025, the company reported a single-quarter main operating revenue of 128 million yuan, a decline of 1.51% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 7.99 million yuan, down 36.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 6.48 million yuan, a decrease of 28.01% year-on-year [2]. - The company's debt ratio stood at 12.32%, with investment income of 3.67 million yuan and financial expenses of -2.07 million yuan [2]. - The gross profit margin was reported at 14.22% [2]. Business Model - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, as well as integrated supply of related diagnostic and nursing medical supplies [2]. - The company primarily operates through an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand companies [2].

Core Viewpoint - The company, Wuzhou Medical, experienced a decline of 1.44% in stock price on December 31, with a trading volume of 118 million yuan and a market capitalization of 2.89 billion yuan [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion sets, and other medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 0.82%, while net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company's overseas revenue accounted for 96.88% of total revenue, benefiting from the depreciation of the Chinese yuan [3] - The average trading cost of the company's shares is 42.66 yuan, with the stock price approaching a resistance level of 43.15 yuan, indicating potential for upward movement if this level is surpassed [6] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Position and Trends - The company operates under the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including overseas expansion and specialized innovation [7] - As of September 30, 2025, the top ten circulating shareholders of Wuzhou Medical saw changes, with notable exits from major funds [9]

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有 限公司 2025 年度持续督导现场培训情况报告 光大证券股份有限公司（以下简称"光大证券""保荐机构"）作为安徽宏宇 五洲医疗器械股份有限公司（以下简称"五洲医疗""公司"）首次公开发行并上 市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市 公司自律监管指引第 13 号——保荐业务》等相关法规要求于 2025 年 12 月 22 日对五洲医疗相关人员进行了现场培训。 现将本次培训相关情况报告如下： 一、出席人员 参加本次培训的五洲医疗人员包括：公司控股股东和实际控制人、董事、高 级管理人员及部分中层以上管理人员等。 培训地点：五洲医疗公司会议室。 培训时间：2025 年 12 月 22 日 14:00-15:00。 培训方式：现场及线上会议。 二、培训内容 现场培训前，光大证券制作了培训讲义，并提前向公司发出了关于本次培训 的通知。 本次现场培训的主题围绕着上市公司公司治理及规范运作、募集资金管理、 股份变动、市值管理四个板块，主要结合《中华人民共和国公司法》、中国证监 会发布的《上市公司募集资金监管规则》《上市公司监管指引第 10 号 ...

Core Viewpoint - Wuzhou Medical has seen a stock price increase of 1.39% with a trading volume of 106 million yuan and a market capitalization of 2.932 billion yuan, indicating positive market sentiment towards the company [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion devices, and other medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while the net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company's overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the Renminbi [3] - The average trading cost of the stock is 42.63 yuan, with the current price approaching a resistance level of 43.15 yuan, indicating potential for upward movement if this level is surpassed [6] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Position - Wuzhou Medical operates under the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including overseas expansion and specialized innovation [7]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]